PMID- 33104959
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210319
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 12
IP  - 1
DP  - 2021 Jan
TI  - Real-World Evaluation of Glycemic Outcomes and Extra-Glycemic Parameters in 
      Diabetic Patients Treated with the Combined Formulation Degludec-Liraglutide 
      (Ideglira).
PG  - 197-209
LID - 10.1007/s13300-020-00945-4 [doi]
AB  - INTRODUCTION: Combination therapy with both basal insulin (BI) and glucagon-like 
      peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with 
      uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release 
      of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA 
      liraglutide (IDegLira) represents an improvement to this therapy. We have 
      conducted a real-world evidence study in Italian patients with T2DM to evaluate 
      whether the encouraging clinical trial results obtained with IDegLira, which 
      became available in Italy in January 2018, can be confirmed in Italian clinical 
      practice. METHODS: This was a multicenter, retrospective, observational study in 
      patients with T2DM treated with IDegLira from January to December 2018. Prior to 
      the initiation of IDegLira therapy, patients were treated with BI with or without 
      one or more concomitant oral antidiabetic drugs (BOT group) or according to the 
      basal bolus protocol (BI and rapid-acting insulin treatment; BB group). RESULTS: 
      A total of 244 patients were included in the present study, of whom 186 were in 
      the BOT group and 58 in the BB group. Following the switch to IDegLira therapy, 
      glycemic control improved in both groups, with significant reductions in glycated 
      hemoglobin after 6 and 12 months of treatment in the BOT group and after 6 months 
      of treatment in the BB group. No gain in body weight and body mass index and 
      reductions in fasting plasma glucose and number of concomitant diabetic 
      medications (in BOT patients) were observed. All results obtained during the 
      study were achieved at a moderate dose of IDegLira. CONCLUSION: The findings from 
      this study show that in a real-world setting, the switch to IDegLira treatment is 
      a valid option for patients who are failing to achieve glycemic control targets 
      and/or struggling with the side effects, such as weight gain and hypoglycemia, of 
      other insulin therapies.
FAU - Zenari, Luciano
AU  - Zenari L
AD  - Unita Operativa di Diabetologia, IRCCS Ospedale Sacro Cuore Don Calabria, Negrar 
      di Valpolicella, VR, Italy. luciano.zenari@sacrocuore.it.
FAU - Da Porto, Andrea
AU  - Da Porto A
AD  - Ambulatorio Diabetologia, Clinica Medica, Azienda Sanitaria Universitaria Friuli 
      Centrale (ASUFC), Udine, Italy.
FAU - De Moliner, Lorena
AU  - De Moliner L
AD  - Ambulatorio Diabetologico, Unita Operativa Geriatria, Ospedale S. Maria del 
      Carmine, Rovereto, TN, Italy.
FAU - Lugli, Francesca
AU  - Lugli F
AD  - Unita Operativa Complessa Diabetologia Territoriale, Azienda Unita Sanitaria 
      Locale (AUSL) Ferrara, Ferrara, FE, Italy.
FAU - Guazzoni, Valeria
AU  - Guazzoni V
AD  - Unita Operativa Diabetologia, Ospedale Maggiore, Lodi, LO, Italy.
FAU - Groppelli, Gloria
AU  - Groppelli G
AD  - Unita Operativa Diabetologia, Ospedale Maggiore, Lodi, LO, Italy.
FAU - Molteni, Laura
AU  - Molteni L
AD  - Centro Diabetologico, Ospedale Sacra Famiglia Fatebenefratelli, Erba, CO, Italy.
FAU - Bracaccia, Massimo
AU  - Bracaccia M
AD  - Diabetologia, Dipartimento di Medicina Interna, Ospedale Santa Maria della 
      Stella, Orvieto, TR, Italy.
FAU - Frison, Vera
AU  - Frison V
AD  - Servizio di Diabetologia, Distretto 4 "Alta Padovana", Cittadella, PD, Italy.
AD  - Azienda ULSS 6 Euganea, Padova, PD, Italy.
FAU - Simioni, Natalino
AU  - Simioni N
AD  - Servizio di Diabetologia, Distretto 4 "Alta Padovana", Cittadella, PD, Italy.
AD  - Azienda ULSS 6 Euganea, Padova, PD, Italy.
FAU - Bonsembiante, Barbara
AU  - Bonsembiante B
AD  - Unita Operativa Diabetologia, Azienda ULSS Euganea, Padova, PD, Italy.
FAU - Miranda, Cesare
AU  - Miranda C
AD  - Clinica di Endocrinologia e Metabolismo, Ospedale Santa Maria degli Angeli, 
      Pordenone, PN, Italy.
FAU - Lapolla, Annunziata
AU  - Lapolla A
AD  - Unita Operativa Diabetologia, Azienda ULSS Euganea, Padova, PD, Italy.
AD  - Dipartimento di Medicina, Universita di Padova, Padova, PD, Italy.
LA  - eng
PT  - Journal Article
DEP - 20201026
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC7843811
OTO - NOTNLM
OT  - Basal insulin
OT  - GLP-1 analogue
OT  - Glycemic control
OT  - Observational study
OT  - Type 2 diabetes mellitus
EDAT- 2020/10/27 06:00
MHDA- 2020/10/27 06:01
PMCR- 2020/10/26
CRDT- 2020/10/26 17:15
PHST- 2020/08/25 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2020/10/27 06:00 [pubmed]
PHST- 2020/10/27 06:01 [medline]
PHST- 2020/10/26 17:15 [entrez]
PHST- 2020/10/26 00:00 [pmc-release]
AID - 10.1007/s13300-020-00945-4 [pii]
AID - 945 [pii]
AID - 10.1007/s13300-020-00945-4 [doi]
PST - ppublish
SO  - Diabetes Ther. 2021 Jan;12(1):197-209. doi: 10.1007/s13300-020-00945-4. Epub 2020 
      Oct 26.